10-K: Adaptive Biotechnologies Soars on Strong Growth, Reduced Losses

Adaptive Biotechnologies reported significant revenue growth and a substantial reduction in net losses for 2025, driven by its MRD business and strategic partnerships.

Summary

• Revenue for 2025 reached $277.0 million, a 55% increase from $179.0 million in 2024.
• Net loss significantly decreased to $59.5 million in 2025, down from $159.6 million in 2024.
• Net cash used in operations was reduced by 52%, from $95.2 million in 2024 to $46.0 million in 2025.
• Adjusted EBITDA turned positive, reaching $12.151 million in 2025, a substantial improvement from a negative $80.371 million in 2024.
• The MRD business grew by 46% to $212.3 million, with clonoSEQ test volume increasing by 39% year-over-year to 105,587 tests delivered.
• Payor coverage for clonoSEQ expanded to over 300 million lives for ALL and MM, over 270 million for CLL, and over 90 million for DLBCL, with new Medicare coverage for MCL recurrence monitoring.
• clonoSEQ is now integrated into 173 Epic and Flatiron EMR sites, facilitating easier test workflow.
• The clonoSEQ assay was utilized in over 180 active trials by more than 40 biopharmaceutical partners, with over 100 trials using MRD as a clinical endpoint.
• The Immune Medicine business revenue increased by 93% to $64.6 million, primarily due to the termination of the Genentech Agreement and a new licensing agreement.
• New non-exclusive agreements were signed with Pfizer Inc. in December 2025 to leverage the TCR discovery platform for therapeutic research in rheumatoid arthritis and broader immunology applications.
• The company's proprietary datasets now include over 5 million paired TCRs to antigens, up from over 2 million, spanning over 20,000 antigens and nearly 50 HLA types.
• Investments in the TCR-depleting antibody program for ankylosing spondylitis were discontinued to prioritize data development and diagnostics.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing as highly positive, reflecting substantial financial improvements, strong growth in the core MRD business, significant regulatory advancements, and strategic partnerships that validate the Immune Medicine platform. While the company still reports a net loss, the trajectory towards profitability and operational efficiency is clearly demonstrated.

Positives

• Achieved significant revenue growth of 55% to $277.0 million in 2025.
• Reduced net loss by over 60% to $59.5 million in 2025, indicating improved financial efficiency.
• Turned Adjusted EBITDA positive at $12.151 million in 2025, a major financial milestone.
• Decreased net cash used in operations by 52%, demonstrating better cash management.
• MRD business revenue grew 46%, driven by a 39% increase in clonoSEQ test volume.
• Expanded payor coverage for clonoSEQ across multiple indications, including new Medicare coverage for MCL recurrence monitoring.
• Successful integration of clonoSEQ into 173 EMR systems, enhancing accessibility for clinicians.
• FDA's Oncologic Drug Advisory Committee (ODAC) voted unanimously for MRD as a primary endpoint for accelerated approval in multiple myeloma, distinguishing clonoSEQ as a leading assay.
• Increased Medicare CLFS price for clonoSEQ to $2,007, a 17% increase, and updated episode pricing to $8,029.
• Entered into two non-exclusive agreements with Pfizer Inc. to leverage the TCR discovery platform, validating the Immune Medicine business's potential.
• Significantly expanded proprietary TCR-antigen mapping datasets from over 2 million to over 5 million matches.
• Maintained a strong intellectual property portfolio with 416 issued and allowed patents and 64 pending applications.

Negatives

• Continued to incur a net loss of $59.5 million in 2025, despite significant improvement.
• Cash, cash equivalents, and marketable securities decreased to $227.2 million in 2025 from $256.0 million in 2024 (excluding Digital Biotechnologies cash).
• The worldwide collaboration and license agreement with Genentech, Inc. was terminated, resulting in the loss of potential future milestone payments and tiered royalties totaling up to $1.8 billion.
• Discontinued investments in the TCR-depleting antibody program for ankylosing spondylitis, indicating a shift away from certain therapeutic development efforts.
• The company has an accumulated deficit of $1.4 billion as of December 31, 2025.
• Certain third-party proxy advisory services have recommended against voting for directors due to the company's governance profile, including issues like majority voting and annual election of directors.

Risks

• Significant net losses since inception and expected future losses, requiring substantial investments to achieve and maintain profitability.
• Uncertainty in market acceptance and adoption of products and services, including coverage and reimbursement decisions for clinical diagnostic products.
• Challenges in managing growth, increasing capacity, and staying current in a rapidly changing industry.
• Potential errors or defects in products or services could harm reputation and lead to product liability claims.
• Reliance on a limited number of suppliers, or in some cases single suppliers (e.g., Illumina), for laboratory equipment and materials, posing supply chain risks.
• Dependence on biopharmaceutical collaborators for drug candidate development and clinical testing, which may fail due to unforeseen events.
• Extensive and evolving government regulations, including healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws, with potential for non-compliance penalties.
• Loss of any member of the senior management team or inability to attract and retain highly skilled personnel could adversely affect the business.
• The validity and enforceability of patents, protection of trade secrets, and other intellectual property matters are subject to challenges and potential litigation.
• Operating results may fluctuate significantly, making future results difficult to predict and potentially causing performance to fall below expectations.
• Dependence on information technology systems and vulnerability to cybersecurity attacks, data loss, or other disruptions.
• The use of artificial intelligence and machine learning presents new risks, including improper data use, flawed models, and changing regulations.
• Future Medicare payment rates are uncertain and could impact clonoSEQ coverage and reimbursement.
• The FDA's Final LDT Rule and potential VALID Act legislation could subject laboratory developed tests (LDTs) to more significant regulatory requirements.
• Modifications to FDA-cleared products may require new FDA clearances, authorizations, or approvals, potentially delaying marketing or requiring recalls.
• Violations of the U.S. Foreign Corrupt Practices Act (FCPA) and other anti-bribery laws could lead to severe penalties as the company expands internationally.
• Patent terms may be inadequate to protect the competitive position of products and services for a sufficient duration.
• The market price of common stock is volatile and subject to substantial fluctuations due to various internal and external factors.
• Obligations under the Revenue Interest Purchase Agreement with OrbiMed could limit cash flow and expose the company to financial risks.
• Substantial future sales or perceived potential sales of common stock could cause the stock price to decline significantly.
• Evolving expectations around corporate responsibility practices, particularly ESG matters, may expose the company to reputational and other risks.
• Provisions in charter documents and Washington law could make an acquisition of the company more difficult and limit shareholder attempts to replace management.

Future Outlook

The company anticipates continued revenue growth in both the short and long term for its MRD business, driven by increased clinical testing volume, expanded patient populations, and optimized payor coverage. Immune Medicine revenue is expected to decrease in the short term due to the Genentech Agreement termination but aims to grow through new partnerships and product research initiatives. The company expects to make progress in obtaining regulatory approval for clonoSEQ in Canada in 2026 and plans to transition all MRD testing to the NovaSeq X Plus over the next two years. Management believes current cash and investments are sufficient for at least the next 12 months and has a pathway to profitability, though it may seek additional capital for expansion and strategic investments.

Management Comments

• "We believe the adaptive immune system is natures most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities."
• "We believe clonoSEQ is uniquely situated for MRD testing in lymphoid cancers, both in the clinic and in biopharmaceutical trials."
• "We believe that we are still in the early stages of clonoSEQ penetration in the indications identified above with significant opportunities to expand adoption."
• "We believe continued validation of clonoSEQ in blood will increase usage, particularly by clinicians in the community setting who perform fewer bone marrow aspirations."
• "We believe this clinical utility data shows that clonoSEQ is uniquely situated in MRD testing to help hematologists improve their ability to assess treatment response, predict long-term patient outcomes, monitor disease burden over time and detect potential relapse."
• "Further, we believe that our clonoSEQ assay has the potential to accelerate the development of drugs in lymphoid cancers and enable treatment decisions which may lower payor cost through the discontinuation of costly drugs that are no longer needed."
• "We believe our current cash, cash equivalents and marketable securities will be sufficient to meet our anticipated cash requirements over at least the next 12 months."
• "We have a pathway to deliver profitability across our business."

Industry Context

StockSavvy.ai notes that Adaptive Biotechnologies operates within the highly competitive and rapidly evolving biotechnology and pharmaceutical industries, particularly in clinical diagnostics, life sciences research, and drug discovery. The significant interest and growth in immune medicine are driving increased competition from various entities, including large biopharmaceutical companies and academic institutions. The company's focus on next-generation sequencing (NGS) and immune medicine platforms aligns with broader industry trends towards precision medicine and data-driven therapeutic development. Regulatory changes, such as the FDA's LDT Final Rule and proposed VALID Act, are reshaping the landscape for laboratory developed tests, potentially increasing compliance burdens but also standardizing the market. The company's expansion of payor coverage and EMR integrations for clonoSEQ reflects a strategic response to market demands for broader access and streamlined clinical workflows.

Comparison to Industry Standards

• clonoSEQ boasts an industry-leading sensitivity of 1 in 1,000,000 cancer cells for MRD detection, positioning it favorably against conventional and next-generation flow cytometry methods.
• clonoSEQ is the first test authorized by the FDA for the detection and monitoring of MRD in multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL), setting a benchmark for regulatory achievement in this space.
• It is also the first and only MRD test to receive Medicare coverage in diffuse large B cell lymphoma (DLBCL), indicating a significant competitive advantage in reimbursement.
• The unanimous vote by the FDA's Oncologic Drug Advisory Committee (ODAC) in favor of using MRD as a primary endpoint for accelerated approval in MM further distinguishes clonoSEQ as a leading assay for lymphoid malignancy drug developers, potentially accelerating drug development timelines compared to traditional endpoints.
• The company's expansion of paired TCRs to antigens from over 2 million to over 5 million, spanning over 20,000 antigens and nearly 50 HLA types, demonstrates a robust data engine that is competitive in the immune medicine discovery landscape, potentially surpassing the scale of many academic or smaller biotech efforts.

Corporate Governance

Legal Proceedings

• The company is not currently a party to or aware of any legal proceedings that are believed to have a material adverse effect on its business, financial condition, or results of operations.

Related Party Transactions

• In July 2011, the company entered into a non-cancelable lease agreement for office and laboratory space in Seattle, Washington, with an individual who was a minority shareholder at the time.

Stakeholder Impact

• **Shareholders**: Potential for dilution if future capital raises involve equity issuance; market price volatility is a risk. Governance provisions may limit shareholder influence on control changes. Positive financial performance and strategic advancements could enhance shareholder value.
• **Patients**: Improved access to highly sensitive MRD testing (clonoSEQ) through expanded payor coverage and EMR integrations. Potential for better-informed treatment decisions and less invasive blood-based testing. Patient support programs (Adaptive Assist) aim to facilitate access and manage financial responsibility.
• **Clinicians**: Enhanced ability to assess treatment response, predict patient outcomes, and monitor disease burden with clonoSEQ. Easier test ordering and results access through EMR integrations.
• **Biopharmaceutical Partners**: Access to advanced clonoSEQ assay for drug development and clinical trials, with potential for accelerated drug approvals due to MRD as a primary endpoint. Collaboration opportunities for TCR-antigen mapping and target discovery.
• **Employees**: Strong company culture, competitive compensation, benefits, and equity grants. Potential for workforce expansion to support increased demand. Risk of losing key personnel due to competition.
• **Payors**: Potential for cost savings through MRD-guided treatment decisions, enabling discontinuation of costly drugs when no longer needed. Increased Medicare reimbursement rates for clonoSEQ.

Next Steps

• Integrate more Epic sites and continue to improve usability by configuring within sites to reduce order to test result complexity through 2026.
• Obtain necessary regulatory approval to enable clonoSEQ testing in Canada in 2026.
• Expand clinical use with current lab partners in several non-U.S. countries.
• Continue to generate data demonstrating the clinical utility of clonoSEQ in additional NHL subtypes.
• Further develop the emerging market for MRD testing for both clinical and biopharmaceutical use cases.
• Generate data demonstrating the role of clonoSEQ to determine which MM patients can safely discontinue treatment and to monitor patients in treatment-free remission.
• Transition all MRD testing to the NovaSeq X Plus sequencers over the next two years.
• Evaluate opportunities to apply Immune Medicine capabilities to develop proprietary clinical diagnostics in areas such as autoimmunity.
• Increase investments in revenue cycle management, including prior authorizations and reimbursement appeals.
• Sign new contracts with private payors and improve contracted rates for existing private payors over time.

Key Dates

Recommendation

Adaptive Biotechnologies demonstrated exceptional financial and operational progress in 2025, marked by a 55% surge in revenue and a significant reduction in net losses, culminating in positive Adjusted EBITDA. The core MRD business is thriving with expanding payor coverage, increased test volumes, and favorable regulatory tailwinds, including the FDA's endorsement of MRD as a primary endpoint in multiple myeloma. New strategic collaborations with major pharmaceutical players like Pfizer validate the company's innovative Immune Medicine platform. These strong indicators of growth, improving financial health, and market leadership, despite ongoing losses, position Adaptive Biotechnologies as a compelling investment opportunity for seasoned investors.

Keywords

Immune Medicine, MRD, clonoSEQ, Adaptive Biotechnologies, Next-Generation Sequencing, Hematologic Malignancies, TCR-Antigen Mapping, Biotechnology, Diagnostics, Oncology, Autoimmunity, FDA, Medicare, Precision Medicine, Immunosequencing, AI, Machine Learning, Corporate Governance, SEC Filing